CN109464449A - A kind of aquatic products antibacterial combination and its application - Google Patents
A kind of aquatic products antibacterial combination and its application Download PDFInfo
- Publication number
- CN109464449A CN109464449A CN201811459005.5A CN201811459005A CN109464449A CN 109464449 A CN109464449 A CN 109464449A CN 201811459005 A CN201811459005 A CN 201811459005A CN 109464449 A CN109464449 A CN 109464449A
- Authority
- CN
- China
- Prior art keywords
- aquatic products
- neomycinsulphate
- antibacterial combination
- arginine
- antibacterials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 73
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims abstract description 44
- 239000003814 drug Substances 0.000 claims abstract description 19
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 102000004452 Arginase Human genes 0.000 claims abstract description 3
- 108700024123 Arginases Proteins 0.000 claims abstract description 3
- 239000004475 Arginine Substances 0.000 claims description 51
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 51
- 241000894006 Bacteria Species 0.000 claims description 32
- 241000251468 Actinopterygii Species 0.000 claims description 31
- 230000004083 survival effect Effects 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 241000223104 Trypanosoma Species 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 7
- 229940030998 streptococcus agalactiae Drugs 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 abstract description 12
- 238000009360 aquaculture Methods 0.000 abstract description 9
- 244000144974 aquaculture Species 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 6
- 230000001954 sterilising effect Effects 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 7
- 241000276701 Oreochromis mossambicus Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002574 poison Substances 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000003641 microbiacidal effect Effects 0.000 description 5
- 229940124561 microbicide Drugs 0.000 description 5
- 239000002855 microbicide agent Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 206010047400 Vibrio infections Diseases 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of aquatic products antibacterial combination and its applications, belong to Medicines in Aquaculture preparation technique field.Technical solution of the present invention main points are as follows: the active component of a kind of aquatic products antibacterial combination, the aquatic products antibacterial combination is made of the raw material that following weight percent matches: neomycinsulphate 0.2%-70.3% and arginase 12 9.7%-99.8%.Antibacterial combination of the invention has better antibiotic and sterilizing effect, expands antibacterials prevention and treatment range, while reducing the use of antibacterials, promotes aquatic health cultivation.
Description
Technical field
The invention belongs to Medicines in Aquaculture preparation technique fields, and in particular to a kind of aquatic products antibacterial combination and its answer
With.
Background technique
In aquaculture, cultivated animals illness rate can be not only greatly reduced in the use of antibiotic, and can be used as dynamic
Object growth promoter is to ensure growing carnivorous demand.However, with aquaculture scale and intensive development, to a certain degree
On accelerate pathogenic microorganism disease generation and antibiotic medicine abuse the problem of, cause food-safety problem to become increasingly conspicuous,
Also serious economic loss is brought.On the one hand, the long-time service with antibiotic in aquaculture causes it in soil, water ring
Accumulation is got up in border and animal body, while remaining in influence human health of antibiotic, also will affect aquaculture itself
Development；On the other hand, a large amount of uses of antibiotic may break cultivated animals inside and outside microecological balance, lead to Tiny ecosystem ring
Border deteriorate or Disorder of Digestion and A orption and cause new disease.Therefore, the antibacterials of highly effective and safe are researched and developed or are reduced using anti-
Bacterium drug is great to the Protection significance of the sound development and ecological environment that promote aquaculture.
Neomycinsulphate is that a kind of widely used Aminoglycosides can press down with broad spectrum antibacterial
Most of bacteriums are made, the bacterial disease prevention and treatment of cultured freshwater fish, shrimps, livestock and poultry is widely used in.Neomycinsulphate is main
In conjunction with bacterial ribosome 30S subunit, inhibit the synthesis of bacterio protein.However, bacterium contacted with neomycinsulphate after pole
It is also easy to produce drug resistance, and the drug has stronger side effect, when a large amount of uses lead to water environment or aquatic products medicament residue
When exceeded, potential security risk can be brought to human health.The clinically less use of the drug, and still exist in aquaculture
It is widely used.
10 kind essential amino acid one of of the arginine as fish body can promote fish body growth and development, participate in body egg
White matter synthesis, also participates in the generation of some important metabolins, moreover, in basal feed adds appropriate arginine and can improve mentioning
The nutritive value of protein in high feed.Ours the study found that fish body immunization, enhancing fish body disease can be improved in arginine
Harmful the first line of defence, the phagocytic activity or immune organ and immunocyte for improving phagocyte to the Scavenging activity of bacterium,
To improve the disease resistance of fish.Using this immunoregulatory function of arginine, cooperate the use of antibacterials, exploitation one
The efficient alternative medicine composition of kind is significant.
Summary of the invention
The technical problem to be solved by the present invention is to provide a kind of aquatic products antibacterial combination and its application, the antibacterials
Composition has better antibiotic and sterilizing effect, expands antibacterials prevention and treatment range, while reducing the use of antibacterials, promotes
The health of aquatic livestock.
The present invention adopts the following technical scheme that a kind of aquatic products antibacterial combination is special to solve above-mentioned technical problem
Sign is that the active component of the aquatic products antibacterial combination is made of the raw material that following weight percent matches: neomycinsulphate
0.2%-70.3% and arginase 12 9.7%-99.8%.
Further preferably, the raw material group that the active component of the aquatic products antibacterial combination is matched by following weight percent
At: neomycinsulphate 0.9%-37.2% and arginine 62.8%-99.1%.
Further preferably, the mass percentage of active component is 30%- in the aquatic products antibacterial combination
100%.
Further preferably, the aquatic products antibacterial combination is solid powder or liquid preparation.
Further preferably, arginine is used to enhance as neomycinsulphate synergist in the aquatic products antibacterial combination
Neomycinsulphate kills the ability of bacterium in vitro.
Further preferably, arginine is used to enhance as neomycinsulphate synergist in the aquatic products antibacterial combination
The ability of neomycinsulphate bacteria removal in vivo.
Further preferably, arginine is used to improve as neomycinsulphate synergist in the aquatic products antibacterial combination
The survival rate of fish body after bacterium infection.
Aquatic products antibacterial combination of the present invention is in preparation for preventing and treating bacteriosis drug or prevention and treatment protozoon
Application in medicine.
Further preferably, the bacterium is tarda or Streptococcusagalactiae, and the protozoon is trypanosoma.
The present invention is through in vitro and in vivo it is experimentally confirmed that the antibacterial combination has than exclusive use neomycinsulphate
Better bactericidal effect can more effectively remove the intracorporal bacterial content of fish, improve the therapeutic effect of fish body bacterium infection, greatly
Amplitude increases fish body survival rate.Compared with previous therapeutic scheme, antibacterial combination of the invention has higher drug effect, sulphur
The content of sour neomycin is also lower.Therefore, under the premise of same or higher control efficiency, neomycinsulphate can be greatly reduced
Usage amount, not only medication is safer, also reduces the generation of bacterial drug resistance and the generation of aquatic products medicament residue problem.This
The antibacterial combination of invention is particularly suitable for the demand of the scale of current cultivation industry, intensive manufacture.Meanwhile immunological regulation
The disease prevention and cure strategy combined with antibacterials is more safe and reliable than previous scheme of combination drug therapy, in fish and livestock and poultry
There is biggish application prospect in disease prevention and cure.
Detailed description of the invention
Fig. 1 is the arginine for injecting various dose, the survival rate of test fish after tarda infection；
Fig. 2 is the arginine of oral various dose, the survival rate of test fish after tarda infection；
Fig. 3 is Survival probability of bacteria after arginine joint various dose neomycinsulphate processing；
Fig. 4 is Survival probability of bacteria after the joint neomycinsulphate processing of various dose arginine；
Fig. 5 is Survival probability of bacteria after arginine and neomycinsulphate processing different time；
Fig. 6 is fish liver after arginine and neomycinsulphate processing, bacterial content in spleen and kidney；
Fig. 7 is arginine and bactericidal effect of the neomycinsulphate composition to Streptococcusagalactiae；
Fig. 8 is the inhibiting effect of arginine and neomycinsulphate composition to trypanosoma.
Specific embodiment
Above content of the invention is described in further details by the following examples, but this should not be interpreted as to this
The range for inventing above-mentioned theme is only limitted to embodiment below, and all technologies realized based on above content of the present invention belong to this hair
Bright range.
Embodiment 1
Host's anti-infectious function can be improved in arginine
Material and method
1, arginic administration
The healthy Tilapia mossambica of selection is grouped at random, every group of equal 20 tail.It takes and takes orally and inject two kinds of administration modes, every kind
The dosage of administration mode is respectively 12.5mg/kg, 25mg/kg, 50mg/kg, 100mg/kg, and volume injected is 100 μ L, control
Group 100 μ L physiological saline of injection.Administration continues one week, once a day.
2, bacterium attacks poison
After last time administration for 24 hours, with 5 × 107CFU/mL tarda injects 100 μ L and carries out attacking poison, in 72h
The death condition for observing Tilapia mossambica checks primary and records death toll, finally calculates survival rate every 12h.
Test result is shown in Fig. 1 and Fig. 2, and in drug administration by injection experiment, in control group, the survival rate of fish body is 40% or so for 24 hours,
It is stable 10% or so later；In the test group of 25mg/kg, the survival rate of fish body is 80% or so for 24 hours, finally stable 40%
Left and right；When the dosage of injection is 50mg/kg, the final survival rate of fish body is 80% or so, is especially in injection dosage
When 100mg/kg, fish body occurs without death, sees Fig. 1.Test result shows that the anti-of Tilapia mossambica can be significantly improved by injecting arginine
Infection ability reduces the death rate of fish body, and when arginic injection dosage is 100mg/kg, survival rate 100%, effect
Fruit highly significant.
Poison is attacked after the arginine of oral various dose the result shows that, in control group, survival rate for 24 hours is 40% or so,
36h survival rate is only 10%；When oral arginine is 12.5mg/kg, survival rate is nearly 40% for 24 hours, finally stable 20%；?
In 25mg/kg experimental group, fish body survival rate reaches nearly 80%, 36h survival rate nearly 50% for 24 hours；The experimental group of oral 50mg/kg
In, it attacks the survival rate after poison for 24 hours and reaches 90%, and in 36h survival rate close to 70%；It is 100mg/kg in oral arginine dosage
Experimental group in, attacking survival rate after poison for 24 hours is 100%, and in 36h, survival rate is still up to 90%.The result shows that no matter which kind of
Administration mode, arginine itself have anti-infectious effect.
Embodiment 2
The extracorporeal disinfecting of antibacterial combination acts on
Material and method
1, Bacteria Culture and survival rate are tested
It connects bacterium and cultivates: taking tarda in L μ ria-Bertani culture medium, 28 DEG C of constant oscillation 16h.
The preparation of reaction system: taking the bacterium solution of the above-mentioned culture of 25mL, is centrifuged 5min, thallus 0.85wt% in 8000rpm
It brine 2 times, is finally suspended with M9 culture medium (containing sodium acetate, magnesium sulfate, calcium chloride), and adjust OD600It is worth to 0.6.It will
Above-mentioned M9 culture medium, appropriate arginine and antibiotic are in corresponding test tube, 28 DEG C of incubation 6h.100 μ L samples are taken to be diluted, it is dense
Degree gradient is 10-106, take 10 μ L contact plates to count, calculate Survival probability of bacteria.
2, the bactericidal effect of microbicide compositions and the dosage of neomycinsulphate are positively correlated
According to the MIC concentration of tarda, 5 neomycinsulphate concentration gradients, respectively 0,4,8,16,32 and are set
64 μ g/mL, and experimental group is added 1740 μ g/mL arginine and is handled bacterium, after bacterial treatment 6h, cooperates with sulphur to arginine
The bactericidal effect of sour neomycin is studied.Test result is shown in that Fig. 3, arginine can effectively improve the sterilizing ability of antibacterials,
Arginic nitrate enhancement is positively correlated with antibiotic concentration and the corresponding nitrate enhancement difference of neomycinsulphate concentration gradient
It is 2,22,213,473 and 2002 times.As seen from the experiment, 1740 μ g/mL arginine cooperate with the antibiotic of 8 μ g/mL to have
Preferable bactericidal effect, experiment in vitro effect, which is equivalent to, is used alone 64 μ g/mL antibiotic, that is to say, that 1740 μ g/ of addition
The usage amount of antibiotic can be greatly reduced in mL arginine.
3, the bactericidal effect of microbicide compositions is positively correlated with arginic dosage
In microbicide compositions constituent, 16 μ g/mL neomycinsulphates add 27-1740 μ g/mL with 2 times of gradients
Arginine handles bacterium 6h, studies influence of the various concentration arginine to neomycinsulphate bactericidal effect.As a result, it has been found that 27 μ g/
ML arginine starts to show the facilitation (P < 0.01) to antibacterials, and bactericidal effect and arginine concentrations are at positive
It closes, 27-1740 μ g/mL arginine is respectively 3,10,29,47,108,223 and to the nitrate enhancement of neomycinsulphate bactericidal effect
389 times, as shown in figure 4, the combined sterilizing effect of 1740 μ g/mL arginine and 16 μ g/mL neomycinsulphates is best.
4, the time effect of microbicide compositions bactericidal effect
The bactericidal effect of 16 μ g/mL neomycinsulphates and 1740 μ g/mL arginine microbicide compositions, as a result, it has been found that with
The effect of the extension of action time, composition is more and more significant.It is 0-12h in the action time of arginine and neomycinsulphate,
A sample is taken every two hours and dilutes contact plate, test result is shown in Fig. 5, in 12h, compared with drug is used alone, joint
For the Survival probability of bacteria of medication group compared to 12206 times of decline, i.e. arginine is more than 12000 times to the synergistic effect of antibacterials.
Embodiment 3
Antibacterial combination removes Fish tissue bacteria test
Material and method
Fish body infection is removed with bacterium tests
Health and Tilapia mossambica up to specification are taken, intraperitoneal injection tarda is infected, and 4 are randomly divided into after infection
Experimental group, respectively arginine and neomycinsulphate group, neomycinsulphate group, arginine group and saline control group.Every group 6
Tail.Arginine and neomycinsulphate dosage are respectively 100mgkg-1And 40mgkg-1, volume injected is 100 μ L.Drug
After processing for 24 hours, fish body liver,spleen,kidney tissue is taken, suitable physiological saline is added by tissue weight, grinding homogenate is prepared into
10wt% tissue liquid is diluted contact plate, computation organization's bacterial population according to the above method later.
Test result is shown in Fig. 6, after bacterium infection, arginine is injected intraperitoneally and/or neomycinsulphate is treated, inquires into essence
Propylhomoserin combines influence of the neomycinsulphate to Fish tissue bacterial content.Inject the sub-lethal dose of tarda, bacterium infection
After for 24 hours, carry out intraperitoneal injection neomycinsulphate 40mg/kg and/or arginine 100mg/kg, treatment for 24 hours after, take fish body liver, spleen,
Kidney etc. is organized and is weighed, and grinding dilution contact plate note bacterial population is carried out.Count of bacteria the result shows that, be used alone neomycinsulphate into
Row therapeutic effect is not obvious, and drug combination can greatly improve bactericidal effect, compared with other groups, measured fish body liver,
Bacterial number in spleen, nephridial tissue has decline respectively.In addition, individually carrying out intraperitoneal injection bacterial number using arginine
Declined, test result shows that arginine can also promote while providing nutrition promotion growth for fish body as nutriment
Into the development of fish body immune function, the ability that body removes tarda infection is improved.
Embodiment 4
Antibacterial combination improves fish body survival rate after bacterium infection
Tilapia mossambica is provided by He'nan Normal University's aquaculture base, and carries out control efficiency test in cultivation base.It is strong
Health Tilapia mossambica is randomly divided into 4 groups, every group of 30 tails.It is mixed again by 1kg fish body and feeds 100mg arginine or 40mg neomycinsulphate, or
100mg arginine and 40mg neomycinsulphate use, and control group is normal bait.It feeds sooner or later daily secondary.It feeds the 3rd day,
Inject 100 L5 × 10 μ7CFU/mL tarda carries out attacking poison, and the death condition of Tilapia mossambica is observed in 72h, is looked into every 12h
It sees primary and records death toll, the statistics accumulation death rate, and calculate relative protection ratio, protective rate=[1- (the administration group death rate/
The control group death rate)] × 100%.The results are shown in Table 1.
The control efficiency that 1 different agents group of table infects tarda
As known from Table 1, compared with arginine group, after the administration of 4 gained antibacterial combination of embodiment, tarda sense
The cumulative mortality of fish drops to 13.33% from 36.66% after dye, and protective rate is increased to 85.2% from 59.3%.It is new with sulfuric acid
Mycin group is compared, and after antibacterial combination administration, the cumulative mortality of fish drops to from 56.66% after tarda infection
13.33%, protective rate is increased to 85.2% from 37%.Test result shows that antibacterial combination substantially increases fish body pair
The control efficiency of tarda infection.
Embodiment 5
Antibacterial combination can expand drug effect range
Material and method
1, Streptococcusagalactiae is cultivated
Streptococcusagalactiae is inoculated in 100mL brain heart infusion broth, 28 DEG C of shaken cultivation 16h.Observe antibacterials combination
Object sterilization test is the same as embodiment 1.
2, the culture of trypanosoma
Trypanosoma grows in insect cell medium, while 5% (v/v) fetal calf serum is added, 0.4g/L sodium bicarbonate,
0.58g/L glutamine, 0.1g/L cysteine, 50mg/mL gentamicin.Trypanosoma culture bottle is placed in 37 DEG C of incubators and trains
It supports 3 days.With 5 × 106The trypanosoma of a/mL cell quantity is initial concentration, after different agents different time is added, hemocytometer
Number plate observes trypanosoma number.
Test result is shown in Fig. 7 and 8, and neomycinsulphate antimicrobial spectrum is mainly Gram-negative bacteria, such as Aeromonas, Edward
Salmonella and vibrios etc., it is weaker to the bactericidal effect of gram-positive bacteria.From Fig. 7 it can also be seen that arginine itself is not shown kills
Bacterium effect, the bactericidal effect of independent neomycinsulphate is not obvious, and antibacterial combination shows pole to Streptococcusagalactiae
Its significant bactericidal effect.
Trypanosoma is a major class pathogenic protozoa, in most cases can only be at present there is no ideal drug
Row prevention.As seen from Figure 8, when arginine or neomycinsulphate are used alone, the inhibitory effect of trypanosoma is not obvious,
And antibacterial combination can significantly inhibit the growth of trypanosoma.
Embodiment 5 the result shows that, antibacterial combination can not only kill Streptococcusagalactiae, can also inhibit trypanosoma
Growth illustrates that it has effects that expand drug fungicidal spectrum.
Embodiment above describes basic principles and main features of the invention and advantage, the technical staff of the industry should
Understand, the present invention is not limited to the above embodiments, and the above embodiments and description only describe originals of the invention
Reason, under the range for not departing from the principle of the invention, various changes and improvements may be made to the invention, these changes and improvements are each fallen within
In the scope of protection of the invention.
Claims (9)
1. a kind of aquatic products antibacterial combination, it is characterised in that the active component of the aquatic products antibacterial combination is by following
The raw material composition of weight percent proportion: neomycinsulphate 0.2%-70.3% and arginase 12 9.7%-99.8%.
2. aquatic products antibacterial combination according to claim 1, it is characterised in that the aquatic products antibacterial combination
Active component be made of the raw material that following weight percent matches: neomycinsulphate 0.9%-37.2% and arginine 62.8%-
99.1%。
3. aquatic products antibacterial combination according to claim 1 or 2, it is characterised in that: the aquatic products antibacterials group
The mass percentage for closing active component in object is 10%-100%.
4. aquatic products antibacterial combination according to claim 1 or 2, it is characterised in that: the aquatic products antibacterials group
Closing object is solid powder or liquid preparation.
5. aquatic products antibacterial combination according to claim 1 or 2, it is characterised in that: the aquatic products antibacterials group
Close the ability that arginine kills bacterium for enhancing neomycinsulphate as neomycinsulphate synergist in vitro in object.
6. aquatic products antibacterial combination according to claim 1 or 2, it is characterised in that: the aquatic products antibacterials group
Arginine is closed in object as neomycinsulphate synergist for enhancing the ability of neomycinsulphate bacteria removal in vivo.
7. aquatic products antibacterial combination according to claim 1 or 2, it is characterised in that: the aquatic products antibacterials group
Close the survival rate that arginine in object is used to improve fish body after bacterium infection as neomycinsulphate synergist.
8. aquatic products antibacterial combination of any of claims 1 or 2 is in preparation for preventing and treating bacteriosis drug or prevention and treatment
Application in protozoon medicine.
9. application according to claim 8, it is characterised in that: the bacterium is tarda or Streptococcusagalactiae, institute
Stating protozoon is trypanosoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811459005.5A CN109464449A (en) | 2018-11-30 | 2018-11-30 | A kind of aquatic products antibacterial combination and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811459005.5A CN109464449A (en) | 2018-11-30 | 2018-11-30 | A kind of aquatic products antibacterial combination and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109464449A true CN109464449A (en) | 2019-03-15 |
Family
ID=65674548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811459005.5A Pending CN109464449A (en) | 2018-11-30 | 2018-11-30 | A kind of aquatic products antibacterial combination and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109464449A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102871996A (en) * | 2012-09-10 | 2013-01-16 | 中国医学科学院医药生物技术研究所 | Antibiotic composition and application thereof |
| WO2014022761A2 (en) * | 2012-08-02 | 2014-02-06 | Kemin Industries, Inc. | Method of protecting active ingredient from degradation during pelleting |
| CN106860467A (en) * | 2017-01-22 | 2017-06-20 | 河南师范大学 | Aspartic acid as neomycinsulphate synergist application |
| CN106860466A (en) * | 2017-01-22 | 2017-06-20 | 河南师范大学 | A kind of synergist for improving neomycinsulphate antibacterial drug effect |
-
2018
- 2018-11-30 CN CN201811459005.5A patent/CN109464449A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014022761A2 (en) * | 2012-08-02 | 2014-02-06 | Kemin Industries, Inc. | Method of protecting active ingredient from degradation during pelleting |
| CN102871996A (en) * | 2012-09-10 | 2013-01-16 | 中国医学科学院医药生物技术研究所 | Antibiotic composition and application thereof |
| CN106860467A (en) * | 2017-01-22 | 2017-06-20 | 河南师范大学 | Aspartic acid as neomycinsulphate synergist application |
| CN106860466A (en) * | 2017-01-22 | 2017-06-20 | 河南师范大学 | A kind of synergist for improving neomycinsulphate antibacterial drug effect |
Non-Patent Citations (1)
| Title |
|---|
| 周建强 等编著: "《畜禽常用药物手册》", 31 January 2003, 安徽科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6166086A (en) | Small molecules that increase the conversion of food to body weight gain | |
| KR20090041411A (en) | Edwardsiella disease in fish and vaccine for streptococcal disease | |
| Subedi et al. | A review: Application of probiotics in aquaculture | |
| CN106822092B (en) | A kind of pharmaceutical composition inhibiting infected by Aeromonas hydrophila | |
| CN103037866A (en) | Fish parasite extermination agent and extermination method | |
| Julinta et al. | Evaluation of efficacy of oxytetracycline oral and bath therapies in Nile tilapia, Oreochromis niloticus against Aeromonas hydrophila infection | |
| CN105232850A (en) | Chinese herbal medicine fermentative extracting solution for preventing and controlling parasitic diseases of freshwater fish and preparation method thereof | |
| CN106860466A (en) | A kind of synergist for improving neomycinsulphate antibacterial drug effect | |
| CN106860467A (en) | Aspartic acid as neomycinsulphate synergist application | |
| CN106727471B (en) | Application of the inositol as Florfenicol synergist | |
| CN107823326A (en) | A kind of fish pathogens bacteria inhibitor | |
| Sasmal et al. | Effect of garlic (Allium sativum) extract on the growth and disease resistance of Carassius auratus (Linnaeus, 1758) | |
| RU2484830C1 (en) | Method of treating cadmium radiation injury and method for producing preparation for cadmium radiation injury | |
| CN109464449A (en) | A kind of aquatic products antibacterial combination and its application | |
| CN106667984A (en) | Small-molecule substance capable of enhancing antibacterial drug effects of florfenicol | |
| CN107823325A (en) | Fish germ inhibitor | |
| CN107412322A (en) | It is a kind of to be used to prevent and treat composition of aquaculture saprolegniasis and preparation method thereof | |
| CN107468714A (en) | A kind of compound formulation for the sterilization of aquatic livestock body surface and its preparation method and application | |
| CN102266346B (en) | Medicament for preventing and controlling coccidiosis | |
| WO1998042204A1 (en) | Infectious disease preventive/remedy for fishes and shellfishes | |
| CN105343879A (en) | Nematode-trapping fungus and vermifuge combined medication box and its application | |
| CN109464448A (en) | A kind of antibacterials compound preparation and its application containing small molecule metabolites | |
| CN110624016B (en) | Composition for preventing and treating streptococcicosis of sturgeon and application thereof | |
| CN109730211A (en) | A kind of alternative malachite green is used for aquaculture and fresh-keeping composition | |
| CN107714838A (en) | A kind of Chinese medicine composition for preventing and treating diarrhea of weaned piglets and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190315 |